| Serial Number | 90796010 |
| Word Mark | EPICENTRX |
| Filing Date | Friday, June 25, 2021 |
| Status | 732 - THIRD EXTENSION - GRANTED |
| Status Date | Tuesday, July 2, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 8, 2022 |
| Goods and Services | Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; biological products, preparations, and substances being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies in the nature of medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; vaccines; pharmaceuticals in the nature of biotechnology platform technology, namely, viral and vaccine vectors for delivery and insertion of function-altering genetic material into human and animal patients, plants, and crops, for visualization of specific cell types, for inducing humoral and cell-mediated responses, for targeting and killing cancer cells, for removing pathological functions, for controlling biological pests, and for boosting crop yields; chemical platform technology, namely, small molecule compounds being pharmaceuticals for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases |
| Pseudo Mark | EPICENT RX |
| Goods and Services | Scientific and medical research and development in the fields of pharmaceuticals, biologics, agriculture, pest control, biotechnology, immunotherapies, and vaccines |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, September 9, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, September 9, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | EpicentRx, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | La Jolla, CA 92037 |
| Party Name | EpicentRx, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | La Jolla, CA 92037 |
| Event Date | Event Description |
| Tuesday, June 29, 2021 | NEW APPLICATION ENTERED |
| Tuesday, March 22, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, September 9, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, March 16, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, March 22, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 22, 2022 | NON-FINAL ACTION E-MAILED |
| Thursday, September 22, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, September 22, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 23, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, October 3, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, October 19, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 8, 2022 | PUBLISHED FOR OPPOSITION |
| Tuesday, November 8, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, July 5, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, January 3, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, July 3, 2023 | SOU TEAS EXTENSION RECEIVED |
| Monday, July 3, 2023 | SOU EXTENSION 1 FILED |
| Monday, July 3, 2023 | SOU EXTENSION 1 GRANTED |
| Friday, December 22, 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, December 22, 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, December 22, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, January 3, 2024 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, January 3, 2024 | SOU EXTENSION 2 FILED |
| Wednesday, January 3, 2024 | SOU EXTENSION 2 GRANTED |
| Friday, January 5, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, July 2, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, July 2, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, July 2, 2024 | SOU EXTENSION 3 FILED |
| Tuesday, July 2, 2024 | SOU EXTENSION 3 GRANTED |